Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Concerning Atezolizumab + Carboplatin + Nab-paclitaxel / Protein-bound paclitaxel & Non-small-cell lung cancer (NSCLC), both the FDA and EMA have approved the combination of Atezolizumab + Carboplatin + Nab-paclitaxel / Protein-bound paclitaxel for the first-line treatment of metastatic Non-small-cell lung cancer (NSCLC) in patients without EGFR or ALK mutations (1).
The multicentre, randomized, open-label, phase III treatment trial NCT02367781 (IMpower130) trial found